EGFR and head and neck squamous cell carcinoma: In HNSCC, we showed that hDT806 effectively suppressed cell proliferation in the HNSCC lines tested, distinct from the EGFR-targeted tyrosine kinase inhibitor erlotinib or the antibody cetuximab.